In:
EMBO Molecular Medicine, EMBO, Vol. 6, No. 5 ( 2014-05), p. 604-623
Kurzfassung:
image A locally delivered, bifunctional recombinant “Sticky‐trap” comprising a VEGF ‐trap and a heparin‐binding domain ( HBD ) can prevent aberrant ocular angiogenesis without affecting systemic physiological VEGF ‐processes. Bifunctional “Sticky‐trap” is comprised of VEGF ‐trap and a carboxy‐terminal HBD . Treatment with recombinant Sticky‐trap can prevent the development of abnormal ocular angiogenesis. Sticky‐trap remains at the site of delivery; thus, it has a local antiangiogenic activity. Sticky‐trap applied in the eye does not compromise systemic physiological VEGF ‐processes, such as wound healing and kidney function.
Materialart:
Online-Ressource
ISSN:
1757-4676
,
1757-4684
DOI:
10.1002/emmm.201303708
Sprache:
Englisch
Verlag:
EMBO
Publikationsdatum:
2014
ZDB Id:
2485479-7
Permalink